Complete Response Reported in Heavily Pre-Treated Lymphoma Patient with LP-284 in Ph 1 Trial July 29, 2025
Positive Mid-year Safety and Efficacy Data from Ph 2 Study of Ampligen® (rintatolimod) + Imfinzi Combo for the Treatment of Pancreatic Cancer Reported July 29, 2025
Ph 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent LGIR-NMIBC published in Reviews in Urology July 29, 2025
Preliminary topline efficacy results from Ph 2 TRIFOUR trial of nadunolimab in advanced TNBC announced July 23, 2025
Tagrisso + chemo demonstrated statistically significant and clinically meaningful improvement in OS in EGFR-mutated advanced lung cancer July 23, 2025
All Primary Endpoints Met in Ph 2 Trial of SLS009 in R/R AML; FDA Guidance Received to Advance into 1L Therapy Study July 23, 2025
Positive Safety Results from Ph 2 Trial of ENV-105 in Advanced Prostate Cancer Announced July 23, 2025
Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with LGIR NMIBC Announced July 23, 2025
XTANDI + Leuprolide combo Significantly Improves Survival Outcomes in Men with Non-Metastatic HSPC with High-Risk Biochemical Recurrence July 15, 2025
Encouraging Response Rates Announced from Ph 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL July 15, 2025
Early Efficacy Data Reported from First TNBC Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in CTCs in Ph 1b Trial July 15, 2025
Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies announced July 15, 2025
Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS Metastatic Breast Cancer Study July 15, 2025
Bria-IMT Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer July 15, 2025
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma July 15, 2025
Primary Results from Ph 2 RAMP 201 Trial of Avutometinib + Defactinib combo in Patients with Recurrent Low-Grade Serous Ovarian Cancer published in JCO July 15, 2025
Encouraging Survival Data in Patients with Metastatic CRC Previously Treated with Leronlimab Announced July 8, 2025
Data from Ongoing Dose Escalation of BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma presented July 8, 2025
BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Ph 3 July 8, 2025
Presentation of positive Ph 1b data for givastomig, nivolumab, and mFOLFOX6 combo in 1L gastric cancer patients announced July 8, 2025
Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial of Certepetide + SoC chemo combo in Metastatic Pancreatic Cancer announced July 1, 2025
Positive pivotal data announced for zidesamtinib in TKI pre-treated patients with ROS1-positive NSCLC from ARROS-1 Ph 1/2 trial July 1, 2025
Ph 3 FORTITUDE-101 of 1L bemarituzumab plus chemotherapy (mFOLFOX6) in gastric cancer patients met primary endpoint of OS July 1, 2025
